Telix’s strategy revolves around expanding its Illuccix distribution and investing in its product pipeline. Illuccix launched in April 2022 and was the second commercially available PSMA imaging agent for prostate cancer. It has gained significant ma… [602 chars]
Long-Term View Unchanged Despite Telix’s Near-Term Cost Growth
RELATED ARTICLES
